Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | IKBKB | O14920 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12484208 | 1.00 | HRH4 (0.59) | HRH4HRH3IKBKBPKMPTPN11 | |
| SCHEMBL12484831 | 0.92 | HRH4 (0.50) | HRH4HRH3IKBKB | |
| SCHEMBL12484826 | 0.92 | HRH4 (0.50) | HRH4HRH3IKBKB | |
| SCHEMBL12268326 | 0.85 | HRH4 (0.80) | HRH4HRH3IKBKB | |
| SCHEMBL12485826 | 0.85 | HRH4 (0.50) | HRH4HRH3IKBKB | |
| SCHEMBL12485833 | 0.85 | HRH4 (0.50) | HRH4HRH3IKBKB | |
| SCHEMBL12484614 | 0.82 | HRH4 (0.64) | HRH4HRH3 | |
| SCHEMBL12484620 | 0.82 | HRH4 (0.64) | HRH4HRH3 | |
| SCHEMBL602573 | 0.78 | HRH4 (0.76) | HRH4HRH3 | |
| SCHEMBL602572 | 0.78 | HRH4 (0.76) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227330-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180111918-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2018-04-26 | — | — | US | disclosed |
| US-9890138-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2018-02-13 | — | — | US | disclosed |
| EP-2678332-B1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2016-05-18 | — | — | EP | disclosed |
| US-20150274700-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2015-10-01 | — | — | US | disclosed |
| EP-2678332-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2014-01-01 | — | — | EP | disclosed |
| US-20130338179-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2013-12-19 | — | — | US | disclosed |
| WO-2012115480-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274700-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | HRH4 4/4885HRH3 50/4885IKBKB 864/4885 |
| US-20130338179-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | HRH4 4/4885HRH3 50/4885IKBKB 864/4885 |
| US-20180111918-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | HRH4 4/4885HRH3 50/4885IKBKB 864/4885 |
| US-10227330-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | HRH2, GIPR, SSTR4 | HRH4 4/4885HRH3 50/4885IKBKB 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.